DelveInsight’s, “Interstitial Lung Diseases Pipeline Insight 2024” report provides comprehensive insights about 120+ ...

The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

Enniskillen author and charity trustee Clare Donohoe recently addressed the Interstitial Lung Disease (ILD) Interdisciplinary Network conference ...

Quantitative CT findings may be useful in identifying early, clinically significant airway disease in patients with rheumatoid arthritis.

Aumolertinib improved progression-free survival vs placebo in patients with unresectable stage III non–small cell lung cancer ...

An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

The toxin strychnine, the primary component of the traditional Chinese medicine, may act in the STAT3 pathway, investigators ...

Enniskillen author and charity trustee Clare Donohoe recently addressed the Interstitial Lung Disease (ILD) Interdisciplinary ...

United Therapeutics’ UTHR third-quarter 2024 earnings of $6.39 per share beat the Zacks Consensus Estimate of $6.18. Earnings ...

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening ...

Tyr Pharma has a pivotal year ahead with key readouts for Efzofitimod, potentially opening a huge market. Find out why ATYR ...

The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...